New combo therapy aims to halt lung cancer progression
NCT ID NCT06014827
First seen May 09, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tests whether adding two types of focused radiation (BgRT and SBRT) to the standard drug osimertinib can better control EGFR-positive non-small cell lung cancer that has started to grow in a few new spots. About 32 adults with advanced lung cancer will receive the combination treatment. The goal is to see if the radiation helps the drug work longer and keeps the cancer from spreading further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
NOT_YET_RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.